| 阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察 |
| |
| 引用本文： | 李小江,姜珊,郭姗琦,刘宏根,贾英杰. 阿帕替尼联合消岩汤治疗晚期非鳞非小细胞肺癌临床疗效观察[J]. 中国肿瘤临床, 2017, 44(14): 701-705. DOI: 10.3969/j.issn.1000-8179.2017.14.609 |
| |
| 作者姓名： | 李小江 姜珊 郭姗琦 刘宏根 贾英杰 |
| |
| 作者单位： | ①.天津中医药大学第一附属医院肿瘤科（天津市 300381） |
| |
| 基金项目： | the Tianjin Municipal Education Commission(20120216)，the Tianjin Key Project of Applied and Advanced Technology Research Program(14JCZDJC36900)，Tianjin Science and Technology Plan Project (No. 15ZXLCSY00020)本文课题受天津市教委课题项目(20120216)，天津市应用基础与前沿技术研究计划重点项目(14JCZDJC36900)，天津市科技计划项目(15ZXLCSY00020) |
| |
| 摘 要： | 目的 研究观察甲磺酸阿帕替尼片联合消岩汤治疗晚期非鳞非小细胞肺癌（non-small cell lung cancer，NSCLC）的临床疗效。 方法 选取晚期非鳞NSCLC患者38例，随机分为阿帕替尼治疗组18例（A组），阿帕替尼联合消岩汤加减方治疗组20例（B组），二组治疗期间均未行手术及放、化疗。 结果 晚期非鳞NSCLC患者服用阿帕替尼后中位无进展生存期（median progression free survival，mPFS）可达3个月，阿帕替尼联合消岩汤组mPFS、客观缓解率（objective response rate，ORR）及疾病控制率（disease control rate，DCR）较阿帕替尼单药组差异无统计学意义（P>0.05）；在改善临床症状及不良反应方面，阿帕替尼联合消岩汤组均优于阿帕替尼单药组（P < 0.05）。 结论 阿帕替尼联合消岩汤加减方治疗晚期非鳞NSCLC可改善患者临床症状，并降低不良反应的发生率。
|
| 关 键 词： | 阿帕替尼 非鳞非小细胞肺癌 消岩汤 VEGF |
| 收稿时间： | 2017-05-28 |
Clinical research on apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer |
| |
| Xiaojiang LI,Shan JIANG,Shanqi GUO,Honggen LIU,Yingjie JIA. Clinical research on apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer[J]. Chinese Journal of Clinical Oncology, 2017, 44(14): 701-705. DOI: 10.3969/j.issn.1000-8179.2017.14.609 |
| |
| Authors: | Xiaojiang LI Shan JIANG Shanqi GUO Honggen LIU Yingjie JIA |
| |
| Affiliation: | ①.Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China②.Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
| |
| Abstract: | Objective:To determine the effect of apatinib combined with Xiaoyan decoction for the treatment of non-squamous non-small cell lung cancer. Methods:Thirty-eight patients with non-squamous non-small cell lung cancer were randomly categorized into apatinib group (group A, 18 cases) and apatinib combined with Xiaoyan decoction group (group B, 20 cases). All patients did not under-go surgical treatment, radiotherapy, or chemotherapy during the study. Results:The median progression free survival (mPFS) of ad-vanced non-squamous non-small cell lung cancer patients reached up to 3 months. The mPFS, objective response rate, and disease control rate of the apatinib combined with Xiaoyan decoction group showed no significant difference and statistical significance (P>0.05). The apatinib combined with Xiaoyan decoction group was superior to the apatinib group with regard to alleviating clinical symp-toms and adverse reactions (P<0.05). Conclusion:Xiaoyan decoction combined with apatinib can improve the clinical symptoms of pa-tients and reduce the incidence of adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer. |
| |
| Keywords: | apatinib non-squamous non-small cell lung cancer Xiaoyan decoction VEGF |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
